| |
|
|
|
Health Network Communications, London
2010/3/26
Day One - Wednesday 24 March 2010
| 08.00 | Registration & coffee
| 08.45 | Opening remarks from the chair
| 09.00 | Keynote address: valuing the benefits of pharmaceuticals
• How should we value an individual’s benefits? • How should we weigh the benefits to different people and conditions? | | |
| 09.25 | Policy challenges in market access for pharmaceuticals in Europe
• Key policy developments over the last 12 months • Cost containment strategies and impact on market access • New deals and pricing models | | |
| 09.50 | Speed networking
 Fun, high speed breaks for making new contacts and exchanging business cards.
| 10.20 | Morning tea
| 10.45 | Innovation and the new PPRS
• The innovation package in the PPRS • Patient access schemes/flexible pricing in the PPRS • Innovation post high quality care for all • The OLS blueprint and the innovation pass | | | Matt Harpur , Senior Policy Manager for Pricing and Cost Effectiveness, Department of Health , United Kingdom
| 11.10 | Strategic medicines management and prescribing in Wales - view from AWMSG
• Prescribing and medicines management • Medicines management achievements • Making the vision a reality | | |
| 11.35 | NICE – latest developments in HTA policy in England and Wales
• Highlights of the updated technology appraisal process • The PPRS and processes for submitting Patient Access schemes • A new evaluation pathway for medical technologies | | |
| 12.00 | Health Technology Assessment in Ireland
• Health policy drivers in Ireland • Pricing and reimbursement framework • HTA practice and the assessment of pharmaceuticals | | |
| 12.25 | Lunch
| 13.25 | France: latest developments in pricing and reimbursement policy | | |
| 13.50 | Germany: latest developments in pricing and reimbursement policy
• Federal Joint Committee – introduction to the operative framework • Cost-effectiveness analyses and ceiling prices in Germany – the way forward • Co-signing procedure for special pharmaceuticals – first experiences | | |
| 14.15 | IQWiG Update
• Examining the new evaluation system, how it is different and what it hopes to achieve • Understanding the main decision making criteria of the institute • Recent results of IQWiQ evaluations | | |
| 14.45 | Delivering quality and value in pharmaceutical products | | |
| 15.15 | Afternoon tea
| 16.30 | Canada: latest developments in pricing and reimbursement policy
• Healthcare system in Canada • History of the Pharmaceutical Provisions of the Patent Act • PMPRB mandate • Price regulatory regime • Regulations and guidelines • Pharmaceutical trends | | |
| 16.45 | USA: healthcare reform and government reimbursement
• US health reform update • Industry’s role in the debate • Changes to government reimbursement programs • Predictions on impact to pharmaceutical pricing & market access
| 17.00 | Canada: the changing pricing and reimbursement environment
• Impact and implications of the new PMPRB price guidelines • HTA and CADTH / Common Drug Review / Joint Oncology Drug Review • Risk sharing, listing agreements and the evolving provincial reimbursement schemes • Parallel trade: decline of Canadian internet pharmacy, is US importation still feasible? • Outlook for P&R in Canada | | |
| 17.30 | Closing remarks from the chair
| 17.45 | Drinks reception
The evening drinks reception is an opportunity to relax and network over drinks with conference attendees.
| 19.00 | End of day one
| |
Day Two - Thursday 25 March 2010
| 08.30 | Registration and coffee
| 09.00 | Opening remarks from the chair | | |
| | NEW THINKING IN PRICING AND REIMBURSEMENT | | | 09.15 | A global view on pharma pricing & market access
• Global payer segmentation • Recent developments and trends • Implications for evolving P&MA evidence needs • Risk sharing: an opinion | | |
| 09.45 | Industry viewpoint on risk sharing agreements
• What are the principles behind the various schemes? • When is risk sharing appropriate and when is it not? • What role should industry play? | | | Anne-Toni Rodgers, Director, Government Affairs and Public Policy - Europe, Baxter World Trade SA, Belgium
| 10.15 | Is risk sharing the way forward?
• Why are companies offering risk-sharing agreements? • Who gains? And what do they gain? • What is the future of risk sharing? Is this a new business relationship? | | | Mr Jim Furniss, Director, Global Market Access, Bridgehead International Ltd, United Kingdom
| 10.45 | Morning tea
| 11.15 | Value communication: the next 10 years
• Downward cost pressure and the role of value communication in healthcare • The problems faced in communicating value • The future of value communication | | |
| 11.45 | The rise of a common EU assessment on drugs
• Collaboration until now • Recent developments • EMEA, MEDEV, EUnetHTA | | |
| 12.15 | Improving access to medicines
• How will new market access models improve availability of new treatments to patients? • What has been done? • What more is to be achieved? • What role should stakeholders play? | | | Confirmed:
Anne-Toni Rodgers, Director, Government Affairs and Public Policy - Europe, Baxter World Trade SA, Belgium
| 13.00 | Lunch
| | MARKET UPDATE EUROPE | | | 13.55 | Opening remarks from the chair | | | Mr Jim Furniss, Director, Global Market Access, Bridgehead International Ltd, United Kingdom
| 14.00 | Italy: latest changes in reimbursement and pricing policy legislation
• Access to medicines in Italy under the NHS • Criteria for pricing and reimbursement • Governance of pharmaceutical expenditure • Experiences with risk sharing and conditional reimbursement | | |
| 14.30 | Norway: latest changes in reimbursement and pricing policy legislation
• Price level in Norway compared to 9 other West-European countries • Price regulation of pharmaceuticals: on patent-segment and segment with generic substitution • Reimbursement system | | | Helga Festøy, Head of Section, Norwegian Mediines Agency, Norway
| 15.00 | Afternoon tea
| | MARKET UPDATE – ASIA | | | 16.00 | Japan pricing and reimbursement system: current and future panoramas and its implications for global pricing strategies
• Pricing and reimbursement system in Japan • P&R data needs and implications for drug development programs • P&R evolution and consequences for the global pricing strategy | | | Susana Murteira, Head of Pricing & Reimbursement Division, Lundbeck SAS, France
| 16.30 | China: latest developments in pricing and reimbursement policy
• Country overview • Economy • Demography • Healthcare system • Pharmaceutical market • Chinese medical security system • Chinese pharmaceutical pricing policy • Opportunities and challenges | | | Dr Ziyan Wang, Manager, Health Economics, Johnson & Johnson, Belgium
| 17.00 | Closing remarks from the chair
| 17.15 | End of conference
| | |
|
|
|
|
|
|
|
|
Organized by:
|
|
Health Network Communications |
|
|
Invited Speakers:
|
|
Head of the Research Department of Standardization, Licensing and Accreditation, Moscow Medical Academy | |
Chief Executive, HIQA, Ireland | |
Chair in Economics, Imperial College, United Kingdom | |
Managing Director, Medaxial Group, United Kingdom | |
Head of Section, Norwegian Mediines Agency, Norway | |
Head of Osmed Unit, AIFA, Italy | |
Director, Global Market Access, Bridgehead International Ltd, United Kingdom | |
Senior Policy Manager for Pricing and Cost Effectiveness, Department of Health , United Kingdom | |
Manager, ZS Associates, United States | |
Dr Peter Kolominsky-Rabas, Former Head of Department, IQWiG, Germany | |
Health Technology Evaluation Director, NICE, United Kingdom | |
Head of Pharmaceuticals, GBA, Germany | |
Head of Pricing & Reimbursement Division, Lundbeck SAS, France | |
President, PDCI Market Access, Canada | |
Vice President Corporate Relations, GlaxoSmithKline, United Kingdom | |
Member if the Board, HAS, France | |
Director, Government Affairs and Public Policy - Europe, Baxter World Trade SA, Belgium | |
Prof Philip Routledge, OBE, Chairman, AWMSG, United Kingdom | |
Head of Reimbursement, CVZ | |
Dr Regina Skavron, Programme Officer, Pharmaceuticals Division, GBA, Germany | |
Dr Martin van der Graaff, Secretary, Reimbursement Committee, CVZ | |
Manager, Health Economics, Johnson & Johnson, Belgium | |
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
ASAP
|
|
|
|
|
|
|
|
Registration:
|
|
Basic packages Currency: GBP (£ Pounds)Gold pass - all 4 days £2,385 2 day conference plus x1 workshop £1,800 2 day conferece £1,215 To register contact Katie Barden on +44 (0) 20 7608 7085 |
|
|
E-mail:
|
|
kbarden@healthnetworkcommunications.com
|
|
|
|
|
|
|
|
|